NeoGenomics Inc (NEO)
Cash ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Cash and cash equivalents | US$ in thousands | 367,012 | 342,488 | 263,180 | 316,827 | 228,713 |
| Short-term investments | US$ in thousands | 19,832 | 72,715 | 174,809 | 198,563 | 67,546 |
| Total current liabilities | US$ in thousands | 301,241 | 96,304 | 89,932 | 87,232 | 73,183 |
| Cash ratio | 1.28 | 4.31 | 4.87 | 5.91 | 4.05 |
December 31, 2024 calculation
Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($367,012K
+ $19,832K)
÷ $301,241K
= 1.28
The cash ratio of NeoGenomics Inc has shown fluctuations over the years based on the provided data. As of December 31, 2020, the cash ratio was 4.05, indicating that the company had $4.05 of cash and cash equivalents for every $1 of current liabilities.
This ratio improved significantly by December 31, 2021, reaching 5.91, suggesting a stronger ability to cover short-term obligations with its available cash resources. However, by the end of 2022, the cash ratio dipped slightly to 4.87 but remained at a relatively healthy level.
In the subsequent years, the cash ratio continued to fluctuate. By December 31, 2023, the ratio stood at 4.31, indicating a slight decrease in the company's liquidity position compared to the previous year. Notably, there was a significant decline in the cash ratio to 1.28 by December 31, 2024, suggesting a potential liquidity challenge for the company in that period.
Overall, the varying trend in NeoGenomics Inc's cash ratio highlights the importance of monitoring liquidity levels and managing cash effectively to ensure the company can meet its short-term obligations and financial commitments.